Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,714 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: CT Scans Clear all
Recruiting Not applicable Interventional

A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Understanding and Management of Coronary Calcium (The Optimal Trial)

NCT07286578
View directory record Official record
Conditions
Cardiovascular Diseases, Myocardial Ischemia, Heart Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Vascular Diseases, Coronary Artery Disease
Interventions
CT(Computed Tomography) guided Percutaneous Coronary Intervention, IVUS (Intravascular Ultrasound) guided Percutaneous Coronary Intervention
Device
Lead sponsor
Fundación EPIC
Other
Eligibility
18 Years to 85 Years
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
5
States / cities
Boston, Massachusetts • Minneapolis, Minnesota • Jersey City, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 2, 2026, 5:46 PM EDT
Active, not recruiting Phase 1 Interventional

Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma

NCT03321643
View directory record Official record
Conditions
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma, Richter Syndrome, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
Atezolizumab, Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Gemcitabine, Magnetic Resonance Imaging, Oxaliplatin, Positron Emission Tomography, Rituximab
Drug · Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
4
States / cities
Duarte, California • La Jolla, California • Sacramento, California + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 2, 2026, 5:46 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Evaluation of Multi-Cancer Early Detection Testing in a High-Risk Military Population: The Sentinel Study

NCT06523868
View directory record Official record
Conditions
Cancer Diagnosis
Interventions
GRAIL Galleri
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
45 Years and older
Enrollment
1,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 2, 2026, 5:46 PM EDT
Active, not recruiting Phase 2 Interventional

Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia

NCT01841723
View directory record Official record
Conditions
Hairy Cell Leukemia, Hairy Cell Leukemia Variant, Recurrent Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia Variant
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Ibrutinib, Ultrasound Imaging
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2029
U.S. locations
5
States / cities
Bethesda, Maryland • Detroit, Michigan • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 2, 2026, 5:46 PM EDT
Active, not recruiting Phase 2 Interventional

Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery

NCT05111574
View directory record Official record
Conditions
Anal Melanoma, Bladder Melanoma, Cervical Melanoma, Esophageal Melanoma, Gallbladder Melanoma, Head and Neck Mucosal Melanoma, Mucosal Melanoma, Nasopharyngeal Mucosal Melanoma, Oral Cavity Mucosal Melanoma, Penile Mucosal Melanoma, Rectal Melanoma, Recurrent Mucosal Melanoma, Sinonasal Mucosal Melanoma, Urethral Melanoma, Urinary System Mucosal Melanoma, Vaginal Melanoma, Vulvar Melanoma
Interventions
Biospecimen Collection, Bone Scan, Cabozantinib S-malate, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Nivolumab, Placebo Administration, Positron Emission Tomography
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
142
States / cities
Auburn, California • Berkeley, California • Fremont, California + 116 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 2, 2026, 5:46 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

South Asians and Coronary Plaque Registry

NCT05367297
View directory record Official record
Conditions
Coronary Artery Disease, Heart Diseases
Interventions
Coronary CT Angiogram
Diagnostic Test
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Sep 2, 2026, 5:46 PM EDT
Recruiting Phase 2 Interventional

Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer

NCT05983276
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Decitabine, Carboplatin, Paclitaxel, Selinexor
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Sep 2, 2026, 5:46 PM EDT
Completed Not applicable Interventional

Texas Hepatocellular Carcinoma Consortium (THCCC) Project 5

NCT02582918
View directory record Official record
Conditions
Carcinoma, Hepatocellular, Liver Neoplasms
Interventions
Outreach with patient education and patient navigation services
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years and older
Enrollment
2,871 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Sep 2, 2026, 5:46 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

NCT03155620
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Histiocytic Sarcoma, Juvenile Xanthogranuloma, Langerhans Cell Histiocytosis, Malignant Glioma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Primary Central Nervous System Neoplasm, Recurrent Rhabdoid Tumor, Recurrent Soft Tissue Sarcoma, Refractory Ewing Sarcoma, Refractory Glioma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Primary Central Nervous System Neoplasm, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Rhabdoid Tumor, Stage III Osteosarcoma AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Osteosarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Stage IVA Osteosarcoma AJCC v7, Stage IVB Osteosarcoma AJCC v7, Wilms Tumor
Interventions
Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan, Computed Tomography, Ensartinib, Erdafitinib, Ivosidenib, Laboratory Biomarker Analysis, Larotrectinib Sulfate, Magnetic Resonance Imaging, Mutation Carrier Screening, Olaparib, Palbociclib, Pharmacological Study, Positron Emission Tomography, Radionuclide Imaging, Samotolisib, Selpercatinib, Selumetinib Sulfate, Tazemetostat, Tipifarnib, Ulixertinib, Vemurafenib, X-Ray Imaging
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
1,377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
168
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 126 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 2, 2026, 5:46 PM EDT
Active, not recruiting Phase 3 Interventional

Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia

NCT03701282
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Ibrutinib, Obinutuzumab, Quality-of-Life Assessment, Venetoclax
Procedure · Drug · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 69 Years
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
864
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 552 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 2, 2026, 5:46 PM EDT
Completed No phase listed Observational

Study With Oral Isovue in Abdominopelvic CT

NCT04453059
View directory record Official record
Conditions
Patients Requiring Abdominopelvic CT With Oral Administration of Contrast
Interventions
Iopamidol
Drug
Lead sponsor
Bracco Diagnostics, Inc
Industry
Eligibility
Not listed
Enrollment
218 participants
Timeline
2021 – 2022
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Sep 2, 2026, 5:46 PM EDT
Completed Phase 1 Interventional

Effects of Vitamin D Replacement in Patients With Primary Hyperparathyroidism (PHPT)

NCT00538720
View directory record Official record
Conditions
Hyperparathyroidism
Interventions
Vitamin D, Four-dimensional computed tomography (4DCT)
Drug · Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
21 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 24, 2019 · Synced Sep 2, 2026, 5:46 PM EDT
Completed Phase 1 Interventional

Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN)

NCT03129061
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
[18F]F-AraG PET Scan, baseline + post anti-PD-1 therapy.
Drug
Lead sponsor
CellSight Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2022 · Synced Sep 2, 2026, 5:46 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Feasibility Study to Determine PET/CT Imaging of Blood Flow to the Bone

NCT03557450
View directory record Official record
Conditions
Normal Subjects
Interventions
PET/CT Scan
Device
Lead sponsor
University of California, Davis
Other
Eligibility
20 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Sep 2, 2026, 5:46 PM EDT
Active, not recruiting Phase 1 Interventional

Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers

NCT07118176
View directory record Official record
Conditions
Anal Carcinoma, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Cholangiocarcinoma, Colorectal Carcinoma, Esophageal Carcinoma, Gastric Carcinoma, Head and Neck Carcinoma, Hematopoietic and Lymphatic System Neoplasm, Hepatocellular Carcinoma, Lung Carcinoma, Malignant Adrenal Gland Neoplasm, Malignant Brain Neoplasm, Malignant Neoplasm of Unknown Primary, Malignant Solid Neoplasm, Malignant Testicular Neoplasm, Malignant Uterine Neoplasm, Neuroendocrine Neoplasm, Ovarian Carcinoma, Pancreatic Carcinoma, Penile Carcinoma, Pleural Carcinomatosis, Primary Peritoneal Carcinoma, Prostate Carcinoma, Salivary Gland Carcinoma, Sarcoma, Skin Carcinoma, Solitary Fibrous Tumor, Thymus Carcinoma, Thyroid Gland Carcinoma, Thyroid Gland Medullary Carcinoma, Urothelial Carcinoma, Vaginal Carcinoma
Interventions
Computed Tomography, Fludeoxyglucose F-18, Gallium Ga 68 FAPi-46, Positron Emission Tomography
Procedure · Other · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 2, 2026, 5:46 PM EDT
Enrolling by invitation Not applicable Interventional

Study to Determine the Clinical Significance of Intravascular OCT-NIRAF

NCT06374498
View directory record Official record
Conditions
Cardiovascular Diseases, Coronary Artery Disease
Interventions
OCT-NIRAF, LUMISIGHT Injection, OCT-NIRAF following LUMISIGHT Injection
Device · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 2, 2026, 5:46 PM EDT
Active, not recruiting Not applicable Interventional

Evaluation of the Impact of Empty Versus Full Bladder in Patients With Prostate Cancer, RELIEF Trial

NCT06037863
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Best Practice, Computed Tomography, Electronic Health Record Review, Imaging Procedure, Questionnaire Administration, Radiation Therapy
Other · Procedure · Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Albert Lea, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 2, 2026, 5:46 PM EDT
Recruiting Phase 2 Interventional

Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder

NCT05786040
View directory record Official record
Conditions
Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder, Polymorphic Post-Transplant Lymphoproliferative Disorder
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, Positron Emission Tomography, Rituximab, Tafasitamab
Procedure · Biological
Lead sponsor
Timothy Voorhees
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
4
States / cities
New Brunswick, New Jersey • Hillsborough, North Carolina • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Sep 2, 2026, 5:46 PM EDT
Recruiting No phase listed Observational

Evaluation of 18F-TFB PET/CT Scan in Patients With Differentiated Thyroid Cancer

NCT05575440
View directory record Official record
Conditions
Differentiated Thyroid Gland Carcinoma, Thyroid Gland Follicular Carcinoma, Thyroid Gland Papillary Carcinoma
Interventions
Computed Tomography, Fluorine F 18 Tetrafluoroborate, Positron Emission Tomography, Survey Administration
Procedure · Radiation · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 2, 2026, 5:46 PM EDT
Active, not recruiting Not applicable Interventional

Evaluating the Clinical Effectiveness of a Patient-specific Silicone Stent

NCT05050591
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Patient-Specific Silicone Airway Stent
Device
Lead sponsor
VisionAir Solutions
Industry
Eligibility
22 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Rochester, Minnesota • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Sep 2, 2026, 5:46 PM EDT
Completed Phase 2 Interventional Results available

Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed

NCT02761057
View directory record Official record
Conditions
Locally Advanced Papillary Renal Cell Carcinoma, Metastatic Papillary Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7, Type 1 Papillary Renal Cell Carcinoma, Type 2 Papillary Renal Cell Carcinoma, Unresectable Renal Cell Carcinoma
Interventions
Biospecimen Collection, Bone Scan, Cabozantinib S-malate, Computed Tomography, Crizotinib, Savolitinib, Sunitinib Malate
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
586
States / cities
Anchorage, Alaska • Kingman, Arizona • Fort Smith, Arkansas + 361 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2025 · Synced Sep 2, 2026, 5:46 PM EDT
Active, not recruiting Phase 2 Interventional

Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia

NCT05453500
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
Interventions
Cyclophosphamide, Doxorubicin, Etoposide, Prednisone, Rituximab, Tafasitamab, Vincristine, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Lumbar Puncture, Biospecimen Collection
Drug · Biological · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 2, 2026, 5:46 PM EDT
Recruiting Phase 2 Interventional

Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma

NCT06510309
View directory record Official record
Conditions
Lymphoma, Marginal Zone Lymphoma, MZL
Interventions
Venetoclax, Rituximab
Drug
Lead sponsor
Gottfried von Keudell, MD PhD
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 2, 2026, 5:46 PM EDT
Recruiting Phase 3 Interventional

Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging

NCT07613099
View directory record Official record
Conditions
Allogeneic Stem Cell Transplantation, Lung Allograft Transplantation, Interstitial Lung Disease, Acute Lung Injury, Pulmonary Arterial Hypertension, Cardiovascular Diseases
Interventions
[18F]FAPI-74, 18F-FAPI-74 PET/CT Imaging
Drug · Diagnostic Test
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 2, 2026, 5:46 PM EDT